Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Dr Dónal O’Mathúna joins Ethics Talk to discuss his article, coauthored with Dr Nawaraj Upadhaya: “Should Children Be Enrolled in Clinical Research in Conflict Zones?”
Christopher W. Reynolds joins Ethics Talk to discuss his article, coauthored with Camilo Sánchez Meertens: “How Should Health Systems Help Clinicians Manage Bias Against Ex-combatants?”